Gene therapy has begun to show promise as a potential therapeutic approaches, with treatment already possible for some forms of inherited blindness.
The Myrovlytis Trust supports investigations into renal gene therapies, which may also have application in a range of genetic kidney disorders.
Learn more about a few of our current projects:
Dr Richard Harbottle: Using non-viral S/MAR plasmid vectors to develop prophylactic gene therapy for Birt-Hogg-Dube Syndrome |
Dr Justin Roth: Development of virus- and cell-based targeting platforms for renal gene therapy |
